Fabrizio Di Costanzo: As liquid biopsy approaches practice, more and more of its potential emerges
Fabrizio Di Costanzo, Resident doctor in Medical Oncology at University of Naples Federico II, shared a post on LinkedIn:
“As liquid biopsy approaches practice, more and more of its potential emerges.
Co-occurring alterations of RB1 and TP53 genes are especially involved into tumours’ neuroendocrine phenotyping.
We investigated some features of such co-aberration, integrating ctDNA data to study how often they define tumour lineage from the very start or are just a milestone in cancer development – also assessing the impact on prognosis of an early diagnosis.
If a detailed (epi-)genome signature is identified, the early labelling of the switch might lead to proper, more suited therapies for patients – without waiting for further pathology or NE serum markers elevation!
With our latest abstract on the topic being displayed at ESMOTAT2025, I’m thankful to our group, Pasquale Rescigno, Luigi Formisano, Christoph Oing and Ruth Plummer.
And also thankful to ESMO – European Society for Medical Oncology for sponsoring me with the Merit Grant – attended a beautiful congress of very remarkable people (plus, visited the breath-taking Paris!)”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023